NCT07303712

Recruiting

Liquid Biopsy for Hepatocellular Carcinoma Molecular Charact...

Palo Alto Veterans Institute for Research Source

Compare

Other study identifiers

Sponsor study identifier

KIS0003ARG

Study Type

observational

Estimated enrollment

12

Locations

1 country

Sites

1

Timeline

Study Start

August 1, 2024

Actual (reported)

Primary Completion

August 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 1, 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Brief Summary

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: recruiting
Estimated enrollment: 12 participants
Study completion date: December 1, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 1, 2024
Actual (reported)
First Submitted
March 17, 2025
Actual (reported)
First Posted
December 26, 2025
Actual (reported)
Primary Completion
August 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 1, 2026
Estimated
Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated: December 26, 2025
Status Verified: October 2025
Last Update Submitted: December 18, 2025

Conditions

Hepatocellular Carcinoma (HCC)

Keywords

Circulating tumor cell (CTC)y90

Outcome Measures

Primary Outcomes (2)

Circulating Tumor Cell (CTC)
blood samples
Baseline, 1 month post treatment, 3 months post treatment, and 6 months post treatment
CTA imaging
imaging of liver tumor
Baseline, 3 months post treatment, 6 months post treatment

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients at VAPAHCS with HCC

You may qualify if:

Age \> or = 18 years

Sponsors & Collaborators

Palo Alto Veterans Institute for Research
Otherlead

Study Sites (1)

VA Palo Alto Health Care System

Palo Alto, California, 94304, United States

RECRUITING

Sirish Kishore, MDCONTACT650-493-5000 ext. 61706

MeSH Terms

Conditions

Carcinoma, HepatocellularNeoplastic Cells, Circulating

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver DiseasesNeoplasm MetastasisNeoplastic ProcessesPathologic Processes

Study Officials

Sirish Kishore, MD
VA Palo Alto Health Care System
PRINCIPAL INVESTIGATOR

Central Study Contacts

Sirish Kishore, MD

CONTACT

650-493-5000 sirish.kishore@va.gov

Luisa Manfredi, MPH

CONTACT

650-493-5000

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 17, 2025

First Posted

December 26, 2025

Study Start

August 1, 2024

Actual (reported)

Primary Completion

August 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

NCT07689175

Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Phase 2Recruiting

NCT06726161

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2Recruiting

NCT06994299

A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma

Phase 2Withdrawn

NCT07075120

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Phase 1Recruiting

NCT06653062

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

Recruiting

NCT04235660

Y90 Radiation Segmentectomy vs SBRT for HCC

Not ApplicableTerminated

HCC confirmed on imaging, BCLC stage 0, A, B, or C

Transarterial Y90 radioembolization approved by multidisciplinary tumor board -

You may not qualify if:

Not eligible for Y90 procedure
Prior surgery or ablation on indicated tumors
Patient unable to complete the follow up visits required for clinical care or research -

Contact the study team to confirm eligibility.

Pathological Conditions, Signs and Symptoms

luisa.manfredi1@va.gov

Study Completion

December 1, 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Last Updated

December 26, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT07303712
Data provider: ClinicalTrials.gov
Source updated: 2025-12-26
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:30:38 UTC

Documents

Informed Consent Form
ICF2024-04-17

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Documents

Locations